PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.30%
Negative net income growth indicates shrinking profitability. Benjamin Graham would label it a concern unless explained by temporary factors.
24.17%
D&A above 15% yoy – Large jump. Philip Fisher would demand significant returns to validate the extra depreciation load.
100.00%
Deferred taxes above 30% yoy – Significant surge. Philip Fisher would demand clarity on what drives this big potential future tax burden.
-9.33%
Negative yoy SBC growth reduces new equity issuance. Benjamin Graham would verify that enough talent investment remains for growth.
-80.33%
A negative yoy change in working capital can free up cash. Benjamin Graham would confirm it is not from falling demand or asset disposal.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.04%
A negative yoy AP change means the firm is paying down supplier credit. Benjamin Graham would see it as lowering short-term liabilities if revenue is stable.
-249.09%
A negative yoy shift in other WC might free up cash flow. Benjamin Graham would confirm the items are not essential to operations or revenue generation.
-101.42%
A negative yoy shift in other non-cash items can lower reported volatility. Benjamin Graham would confirm it is not concealing real operational costs or artificially inflating net income.
-72.30%
Negative yoy CFO growth indicates a decline in core cash generation. Benjamin Graham would treat it as a serious warning unless cyclical factors explain it.
-455.28%
A negative yoy CapEx shift boosts near-term FCF if capacity is adequate. Benjamin Graham would see it as beneficial unless future growth is sacrificed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Above 20% yoy – Large jump. Philip Fisher would demand clarity on whether these “other” items overshadow core expansions.
-427.62%
A negative yoy shift suggests smaller outflows or net inflows if disposals exceed invests. Benjamin Graham would see a short-term FCF benefit unless growth is compromised.
No Data
No Data available this quarter, please select a different quarter.
53916.27%
Issuance above 15% yoy – Significant equity raise. Philip Fisher would require a very compelling reason to risk heavy shareholder dilution.
No Data
No Data available this quarter, please select a different quarter.